Tel：
(86)(21)60969600
Add: Building 28, Lane 588, Tianxiong Road. Shanghai, P. R. China
Shanghai, China – OnMarch 1, 2021, Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort EP”) has recently obtainedregistration approval by the Australia TGA for its proprietary equipment andaccessories, marking its entry into Australian market.
Arrhythmia is a common cardiovasculardisease, and severe arrhythmia is the main cause of sudden cardiac death.Radiofrequency ablation surgery is one of the most importantnon-pharmacological treatments for arrhythmias. The approved equipment andaccessories, including Columbus™ 3D EP Navigation System, Columbus™ Cardiac Electrophysiology Stimulator, OptimAblate™ Cardiac RF Generator, OptimAblate™Irrigation Pump and OptimAblate™ Tubing Set, areintended for the rapid diagnosis and effective treatment of arrhythmias.
The TGA approval means these products willsoon enter the Australian market. These products will provide a completeintegrated therapeutic solution in electrophysiology for local patients anddoctors, laying a solid groundwork for the company’sfurther exploration in the Oceania market.
